FY2025 EPS Estimates for AbbVie Cut by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has lowered its FY2025 earnings per share (EPS) estimate for AbbVie to $10.82, down from a previous estimate of $12.05, while maintaining an "Overweight" rating and a target price of $250.00.
• Bank of America recently raised its target price for AbbVie from $220.00 to $251.00, reflecting a positive outlook amid mixed analyst ratings on the stock.
• AbbVie announced a quarterly dividend of $1.64 per share, bringing its annualized dividend to $6.56, with a yield of 2.8%.

AbbVie Inc. (NYSE:ABBV - Free Report) - Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of AbbVie in a report issued on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now expects that the company will post earnings of $10.82 per share for the year, down from their prior estimate of $12.05. Cantor Fitzgerald currently has a "Overweight" rating and a $250.00 target price on the stock. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share.

A number of other equities research analysts have also weighed in on the stock. Bank of America lifted their target price on shares of AbbVie from $220.00 to $251.00 and gave the company a "neutral" rating in a research note on Friday, October 3rd. Wall Street Zen lowered shares of AbbVie from a "buy" rating to a "hold" rating in a research note on Saturday. Evercore ISI boosted their price objective on shares of AbbVie from $207.00 to $222.00 and gave the stock an "outperform" rating in a research note on Monday, September 22nd. Guggenheim boosted their price objective on shares of AbbVie from $216.00 to $227.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Finally, UBS Group set a $251.00 price objective on shares of AbbVie in a research note on Friday, October 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $231.90.

AbbVie Trading Up 0.1%

Shares of ABBV opened at $230.88 on Monday. The firm's 50-day moving average price is $214.84 and its 200-day moving average price is $196.71. The firm has a market capitalization of $407.86 billion, a price-to-earnings ratio of 109.94, a PEG ratio of 1.42 and a beta of 0.51. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. AbbVie has a 1-year low of $163.81 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). The company had revenue of $15.42 billion for the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company's revenue for the quarter was up 6.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.65 EPS.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Shareholders of record on Wednesday, October 15th will be issued a $1.64 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $6.56 annualized dividend and a yield of 2.8%. AbbVie's payout ratio is 312.38%.

Insider Activity

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the transaction, the executive vice president directly owned 177,292 shares of the company's stock, valued at approximately $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Nicholas Donoghoe sold 13,295 shares of AbbVie stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the completion of the transaction, the executive vice president directly owned 58,247 shares of the company's stock, valued at $11,562,611.97. This trade represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.08% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. TD Capital Management LLC raised its holdings in AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company's stock worth $27,000 after buying an additional 58 shares during the last quarter. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie during the second quarter valued at approximately $25,000. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie during the second quarter valued at approximately $26,000. Abound Financial LLC purchased a new position in shares of AbbVie during the first quarter valued at approximately $30,000. Finally, Spurstone Advisory Services LLC purchased a new position in shares of AbbVie during the second quarter valued at approximately $28,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.